Cover Image
市場調查報告書

RNAi藥物遞輸:技術及全球市場

RNAi Drug Delivery: Technologies and Global Markets

出版商 BCC Research 商品編碼 306915
出版日期 內容資訊 英文 261 Pages
訂單完成後即時交付
價格
Back to Top
RNAi藥物遞輸:技術及全球市場 RNAi Drug Delivery: Technologies and Global Markets
出版日期: 2014年06月30日 內容資訊: 英文 261 Pages
簡介

RNAi(RNA干擾)藥物遞輸的全球市場規模,預計將從2012年概算實際成果的93億美元、2013年的117億美元之後連續數年展現出27.2%的年複合成長率,到2018年達到約388億美元。

本報告以RNAi藥物遞輸的全球市場為焦點,除了分析·預測其概況及2013-2018年這段期間的交易規模轉變之外,更彙整技術和相關療法,市場趨勢,競爭環境,再加上主要企業的簡介等最新資訊。

第1章 簡介

  • 調查的目標和目的
  • 調查理由
  • 報告的範圍
  • 推薦用戶層
  • 調查方法
  • BCC Research公司的相關報告
  • 分析師經歷
  • BCC Research公司WEB網站
  • 免責聲明

第2章 摘要

第3章 概要

  • 概要
    • 所謂RNAi
    • RNAi這個療法
  • RNAi的潛力
  • RNAi技術
    • RNAi的機制:其作用
    • 使用siRNA(小干涉RNA)療法的理由
    • siRNA的遞送
    • siRNA的設計和方法論
      • 遞送的障礙
      • 細胞吸收和siRNA
      • siRNA遞送與問題點
  • 商業性利益
    • 利用微脂體的遞送
    • 非微脂體方式
    • 反義核酸療法
    • 內因性低分子RNA的等級
    • 未來發展預測

第4章 RNAi藥物遞輸

  • RNAi的發現
  • RNAi療法遞送技術的重要性
    • 藥物遞輸技術
  • 新技術的必要性
  • 針對藥物遞輸·開發的siRNA遞送工具
    • siRNA篩檢
    • shRNA篩檢
  • 應該克服的RNAi遞送問題點
  • 各種遞送技術
    • 利用媒介的遞送
    • 針對生物內實驗利用媒介遞送RNAi
      • iRNA遞送用病毒媒介
    • 非病毒siRNA遞送
    • 專利遞送平台
    • 全身遞送策略
    • 局部遞送
    • 表現基礎策略
    • NAi遞送和療法開發的影響
    • iRNA為對象的現行非生物學遞送媒體
    • 轉染技術
    • 主要企業
    • 摘要

第5章 利用RNAi的療法

  • 利用RNAi的療法:新的產業環境
  • RNAi遞送療法
    • RNAi與癌症治療
  • 法規問題
    • 臨床實驗:RNAi
    • 臨床上其他候補策略
    • 結束計劃
    • 其他的計劃
  • 治療用RNAi的開發
    • ALN-VSP02
    • Alnylam公司的ALN-RSV:呼吸器合胞體(RS)病毒
    • 對肺移植患者的呼吸器合胞體(RS)病毒感染的ALN-RSV01治療
  • 課題:利用RNAi的療法

第6章 - RNAi環境

  • 今後趨勢
    • 所謂RNA干擾
    • RNAi這個研究方式
    • RNAi設計的重要性
    • 事實與時間軸
    • 市場成長
    • RNAi的全球市場
    • 研究用的RNAi技術·產品
    • RNAi工具及試劑市場
    • RNAi和治療方法
    • 主要企業
    • RNAi療法的未來性

第7章 RNAi藥物遞輸 - 市場資料

  • 市場趨勢
  • 市場規模及成長率
    • RNAi藥物
    • 醫藥品的全球市場
  • 藥物遞輸技術環境
    • 藥物遞輸市場
    • 肺部藥物遞輸
  • RNAi市場分析
    • 主要企業
    • RNAi市場動態
    • RNAi核酸藥物遞輸
    • 核酸核酸適體系奈米粒子
    • 標的遞送
    • 綜合奈米粒子市場
    • 標的體組織療法的遞送
    • RNAi遞送手法和目前開發情形
    • 利用RNAi療法的開發
    • 奈米粒子利用的遞送法
    • 微脂體與奈米粒子
    • 聚合物
    • CALANDO PHARMACEUTICALS
    • INTRADIGM
  • MESOPOROUS SILICA NANOPARTICLES
  • 蛋白質或胜肽系奈米粒子
  • BACTERIOPHAGE BASED NANOPARTICLES
    • SOLSTICE BIOLOGICS
    • GENZYME
    • QUARK PHARMACEUTICALS
  • 患者的RNAi給藥
    • ROCHE
  • DICERNA PHARMACEUTICALS
  • 結論

第8章 RNAi藥物遞輸策略和目前市場動態

  • 系統性配送法
  • RNAi藥物遞輸的問題點
  • RNAi療法市場
  • RNAi的商業性發展前途
  • RNAi的治療學的發展前途
  • 近幾年的發展

第9章 企業簡介

第10章 有關RNAi的市場變化

  • 知識產權和專利問題
  • 最新專利新聞
  • RNAi專利許可證
  • 主要企業專利
  • 聯盟,聯合,產業收購
  • 結論

第11章 參考文獻一覽

目錄
Product Code: BIO076B

REPORT HIGHLIGHTS

The global market for RNAi drug delivery technologies reached nearly $9.3 billion in 2012 and nearly $11.7 billion in 2013. This market is expected to grow to $38.8 billion in 2018, with a compound annual growth rate(CAGR) of 27.2% from 2013 to 2018.

This report provides:

  • An overview of the global market for RNA interference (RNAi) in major therapeutic and drug delivery areas.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Details on application areas including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism.
  • Identification of the driving factors for demand in the market
  • Discussion of emerging technologies.
  • Comprehensive company profiles of major players in the industry.

STUDY GOALS AND OBJECTIVES

This BCC Research report, RNAI Drug Delivery: Technologies and Global Markets, provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based therapeutic companies are profiled. This report also provides forecasts for market growth to 2018 across RNAi market segments, reviews the latest advances in RNAi drug delivery technologies, and assesses the competitive landscape across RNAi therapeutic areas.

REASONS FOR DOING THE STUDY

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research. It may even surpass polymerase chain reaction (PCR) as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report assesses this emerging commercial market and maps the key RNAi therapeutic and drug delivery players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government, and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics. This report analyzes emerging RNAi molecules and delivery technologies and examines new molecular targets and pipeline drugs. It also evaluates competitors and collaborators in the developing RNAi technologies and examines the latest RNAi-related patenting trends.

SCOPE OF REPORT

The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based developers are profiled. This report also provides forecasts for market growth to 2018 across major RNAi market segments. This report provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of preclinical, alliance management, discovery, and technology development marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays ranging from drug discovery, in vitro and in vivo screening, in vivo model development, and pharmacokinetics. She has experience working with early start-ups.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2013-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • OVERVIEW
    • WHAT IS RNAI?
    • RNAI AS THERAPY
  • THE PROMISE OF RNAI
    • TABLE 1: VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION
  • RNAI TECHNOLOGY
    • RNAI MECHANISM: HOW DOES IT WORK?
    • WHY SIRNA THERAPEUTICS?
    • SIRNA DELIVERY
    • RNAI DESIGN AND METHODOLOGIES
      • Barriers to Delivery
      • Cellular Uptake and siRNAs
      • SiRNA Delivery and Challenges
  • COMMERCIAL INTEREST
    • LIPOSOME-BASED DELIVERY
    • NONLIPOSOMAL METHODS
      • Nucleic-acid Aptamers
      • Aptamers as Therapeutics
        • TABLE 2: THERAPEUTICALLY TARGETED APTAMERS
      • Aptamers for siRNA Delivery
      • Challenges: Aptamer-siRNA Delivery
      • Commercial Interest for Aptamers
      • Nanotechnology-based Delivery
      • Nanoparticles
      • Advantages
        • TABLE 3: REQUIRED STEPS FOR DEVELOPING EFFECTIVE RNAI DRUG
    • ANTISENSE THERAPY
      • Selected Companies
    • CLASSES OF ENDOGENOUS SMALL RNAS
      • siRNA
      • miRNA
    • OUTLOOK

CHAPTER 4 - RNAI DRUG DELIVERY

  • RNAI DISCOVERED
  • IMPORTANCE OF DELIVERY FOR RNAI THERAPEUTICS
    • DRUG DELIVERY TECHNOLOGIES
      • TABLE 4: ROLE OF DRUG DELIVERY
  • NEED FOR NEW TECHNOLOGIES
  • RNAI DELIVERY-TOOL FOR DRUG DISCOVERY AND DEVELOPMENT
    • siRNA Screening
    • shRNA Screening
  • CHALLENGES TO OVERCOME IN DELIVERING RNAI
    • TABLE 5: DIFFERENT RNAI DELIVERY APPROACHES
  • DIFFERENT DELIVERY TECHNIQUES
    • VECTOR-BASED DELIVERY
    • VECTOR-BASED RNAI FOR IN VIVO RNAI EXPERIMENTS
      • TABLE 6: COMPANIES WITH PLASMID RNAI VECTORS
      • Viral Vectors for Delivery of siRNA
        • TABLE 7: RNAi VIRAL VECTOR DELIVERY METHODS
        • TABLE 8: LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES
    • NONVIRAL SIRNA DELIVERY
      • Hydrodynamic IV Injection
      • Electroporation
      • Carrier-mediated Delivery
      • Lipid-based siRNA Delivery
      • Polymer-Based siRNA Delivery
      • Combined Lipid and Polymer Carriers for a Better siRNA Delivery
      • Peptide-Mediated siRNA Delivery
      • Antibody-Mediated siRNA Delivery
      • Dendrimer-Mediated siRNA Delivery
      • Stem-Cell-Based Delivery
      • Light Controllable Delivery of siRNA
    • PROPRIETARY DELIVERY PLATFORMS
    • SYSTEMIC DELIVERY STRATEGIES
      • TABLE 9: THERAPEUTIC STRATEGIES
    • LOCALIZED DELIVERY
      • Targeted Cellular Delivery
    • EXPRESSION-BASED STRATEGIES
    • RNAI DELIVERY AND IMPACT ON THERAPEUTIC DEVELOPMENTS
      • New Developments
      • Tissue Delivery
      • RNAi as Drugs
    • CURRENT NONBIOLOGICAL DELIVERY VEHICLES FOR SIRNAS
      • Simple Excipients
        • TABLE 10: SIMPLE EXCIEPIENTS FOR RNAI DELIVERY
    • TRANSFECTION TECHNIQUES
      • Electroporation
      • Conjugates
        • TABLE 11: CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS
      • Peptides and Proteins
      • Dynamic Polyconjugate Transfection
      • Polymer Carriers/Nanoparticles
        • TABLE 12: POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY
      • Liposomes and Lipoplexes
        • TABLE 13: LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY
      • Case Study-siRNA in Mammalian Cells
        • Gene Silencing (RNAi) in Neuronal Cells
      • Concerns about RNAi Delivery
    • KEY COMPANIES
      • siRNA Transfection
        • TABLE 14: COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA
      • Delivery as Particles or Complexes
      • Delivery with Modifications
    • SUMMARY

CHAPTER 5 - RNAI-BASED THERAPEUTICS

  • RNAI-BASED THERAPEUTICS: THE EMERGING INDUSTRY LANDSCAPE
  • DELIVERING RNAI THERAPEUTICS
    • RNAi and Cancer Therapeutics
  • REGULATORY CONCERNS
  • RNAI IN CLINICAL TRIALS
    • Clinical Trials: RNAi
      • TABLE 15: THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE
    • Other Candidates in Clinic
    • Terminated Programs
    • Other Programs
  • THERAPEUTIC RNAI DEVELOPMENTS
    • ALN-VSP02
    • Alnylam's ALN-RSV: Respiratory Syncytial Virus
    • ALN-RSV01 Treatment of Respiratory Syncytial Virus Infection in Lung Transplant Patients
      • TABLE 16: RECENT UPDATES: RNAi CLINICAL TRIALS
      • TABLE 17: CLINICAL TRIALS: RNAI-SYSTEMIC DELIVERY
  • CHALLENGES: RNAI-BASED THERAPIES

CHAPTER 6 - RNAI LANDSCAPE

  • FUTURE TRENDS
    • WHAT IS RNA INTERFERENCE?
      • Locked Nucleic Acid
    • RNAI AS A RESEARCH TOOL
    • THE IMPORTANCE OF RNAI DESIGN
    • FACTS AND TIMELINES
    • MARKET GROWTH
    • GLOBAL MARKET FOR RNAI
      • TABLE 18: GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 1: GLOBAL RNAI RESEARCH SALES, 2010-2018 ($ MILLIONS)
      • TABLE 19: GLOBAL TOOLS, REAGENTS AND THERAPEUTIC MARKET FOR RNAI, THROUGH 2018 ($ MILLIONS)
      • FIGURE 2: GLOBAL TOTAL MARKET FOR RNAI, 2012-2018 ($ MILLIONS)
    • RNAI TECHNOLOGIES/PRODUCTS IN RESEARCH APPLICATIONS
      • RNAi Screening for Drug Discovery
      • Individual versus Pooled siRNAs
      • Necessary Controls
      • High-throughput siRNA Delivery
    • RNAI TOOL AND REAGENT MARKET
      • Transfection Products
      • Key Companies
        • TABLE 20: RNAi COMPANIES WITH TRANSFECTION REAGENTS
      • RNAi Reagents
      • Lipid Transfection
      • In Vivo Reagents and Therapeutics
      • RNAi Experiments in Animals
    • RNAI AND THERAPEUTICS
      • TABLE 21: IN VIVO DELIVERY
      • Viral-based Transfections
        • TABLE 22: VIRAL BASED DELIVERY TECHNOLOGIES
      • Other Methods
      • RNAi Reagents and Kits
        • TABLE 23: RNAI TOOL/REAGENT COMPANIES
    • KEY COMPANIES
      • Inc.Lonza
    • THE FUTURE OF RNAI THERAPEUTICS

CHAPTER 7 - RNAI DRUG DELIVERY-MARKET DATA

  • MARKET TRENDS
  • MARKET SIZE AND GROWTH
    • RNAI DRUGS
    • GLOBAL PHARMACEUTICAL MARKET
      • TABLE 24: GLOBAL PHARMACEUTICAL SALES AND FORECAST THROUGH 2018 ($ BILLIONS)
      • FIGURE 3: GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($ BILLIONS)
      • Pharmaceutical Growth Rates
      • Emerging Markets
        • TABLE 25: TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 ($ BILLIONS)
      • U.S. Pharmaceutical Industry
      • Global Pharmaceutical Companies
        • TABLE 26: TOP 25 PHARMACEUTICAL COMPANIES, GLOBAL SALES, 2012 AND 2013 ($ MILLIONS)
        • TABLE 27: TWELVE LARGEST PHARMACEUTICAL COMPANIES 2010 ($ MILLIONS)
  • DRUG DELIVERY TECHNOLOGY LANDSCAPE
    • DRUG DELIVERY MARKET
      • Drug Delivery Technologies and Global Market
        • TABLE 28: TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
        • FIGURE 4: TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
        • TABLE 29: KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET
      • European Drug Delivery Market
        • TABLE 30: GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS) 123
        • FIGURE 5: GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
      • Oral Drug Delivery
        • TABLE 31: GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
        • FIGURE 6: GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($ MILLIONS)
      • Implantable and Injectable Drug Delivery
        • TABLE 32: GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 ($ MILLIONS)
        • FIGURE 7: GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 ($ MILLIONS)
      • Transdermal Drug Delivery
        • TABLE 33: GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
        • FIGURE 8: GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
      • Drug Delivery Market in the U.S.
        • TABLE 34: U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST THROUGH 2018 ($ MILLIONS)
        • FIGURE 9: U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • PULMONARY DRUG DELIVERY
      • TABLE 35: TOP ASTHMA AND COPD DRUGS
      • TABLE 36: GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 10: GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • RNAI MARKET ANALYSIS
    • LEADING PLAYERS
      • Rxi Pharmaceuticals
      • Tekmira Pharmaceuticals
      • Arrowhead Research Corp.
    • RNAI MARKET DYNAMICS
    • RNAI NUCLEIC ACID DRUG DELIVERY
      • TABLE 37: GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 11: GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($ MILLIONS)
      • TABLE 38: GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 12: GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS)
    • NUCLEIC ACID APTAMER-BASED NANOPARTICLES
    • TARGETED DELIVERY
    • THE TOTAL NANOPARTICLE MARKET
      • TABLE 39: GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 13: GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 ($ MILLIONS)
    • DELIVERY OF THERAPEUTICS TO THE TARGET TISSUES
      • TABLE 40: GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 14: GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES, MARKET, 2012-2018 ($ MILLIONS)
    • RNAI DELIVERY APPROACHES AND CURRENT DEVELOPMENTS
    • DEVELOPMENT OF RNAI-BASED THERAPEUTICS
    • NANOPARTICLE-BASED DELIVERY
      • RNAi Drugs under Investigation
        • TABLE 41: NON-VIRAL SIRNAS
    • LIPOSOME AND NANOPARTICLES
    • POLYMERS
    • CALANDO PHARMACEUTICALS
    • INTRADIGM
  • MESOPOROUS SILICA NANOPARTICLES
  • PROTEIN OR PEPTIDE-BASED NANOPARTICLES
  • BACTERIOPHAGE BASED NANOPARTICLES
    • SOLSTICE BIOLOGICS
    • GENZYME
      • TABLE 42: KEY RNAI COMPANIES
    • QUARK PHARMACEUTICALS
      • Marina Biotech
      • Lipid and Polymer-Based Systems
        • TABLE 43: LIPID-BASED TECHNOLOGIES-COMPANIES
        • TABLE 44: POLYMER-BASED AND LIPOSOMAL RNAi DELIVERY SYSTEMS (%)
  • RNAI INTO THE PATIENTS
    • ROCHE
      • Polyconjugate Technologies
      • Polymer-Based Systems-Limitations
      • RXi
        • TABLE 45: NANOPARTICLES TECHNOLOGIES-COMPANIES
      • Single siRNA Delivery
        • TABLE 46: SINGLE RNAi DELIVERY TECHNOLOGIES, COMPANIES
  • DICERNA PHARMACEUTICALS
  • CONCLUSIONS

CHAPTER 8 - RNAI DRUG DELIVERY STRATEGIES AND CURRENT MARKET DYNAMICS

  • SYSTEMIC DELIVERY STRATEGIES
  • CHALLENGES WITH RNAI DRUG DELIVERY
  • RNAI THERAPEUTIC MARKET
    • TABLE 47: SELECTED RNAI-BASED DRUGS IN DEVELOPMENT
  • COMMERCIAL POTENTIAL OF RNAI
    • TABLE 48: COMMERCIAL POTENTIAL OF RNAI
  • RNAI'S THERAPEUTIC POTENTIAL
    • HOW DOES RNAI WORK?
    • RNAIS AND PRECLINICAL AND CLINICAL STUDIES
      • CEQ508 in Clinic
      • RNAi as a Therapy
    • GLOBAL MARKET OF THERAPEUTIC RNAI
      • RNAi Therapeutic Market to Play a Key Role by 2020
        • TABLE 49: GLOBAL MARKET FOR THERAPEUTIC RNAi, THROUGH 2018 ($ MILLIONS)
        • FIGURE 15: GLOBAL MARKET FOR THERAPEUTIC RNAi, 2013 AND 2018 ($ MILLIONS)
        • TABLE 50: RNAi THERAPEUTIC COMPANIES
      • Benitec's Clinical Program
        • TABLE 51: ONGOING RNAi CLINICAL TRIALS: NANOPARTICLE DRUG DELIVERY
      • MicroRNA and Market
    • MIRNA MARKET
      • TABLE 52: TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 16: TOTAL MIRNA MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
      • TABLE 53: TOTAL MIRNA MARKET SALES, 2008 (%)
  • RECENT DEVELOPMENTS
    • RNAI LICENSING DEALS
      • TABLE 54: MAJOR RNAI LICENSING DEALS, 2005-2010
    • TARGETED DELIVERY
      • TABLE 55: SYSTEMIC DELIVERY TECHNOLOGIES, COMPANIES
    • KEY THERAPEUTIC COMPANIES AND HISTORICAL DEVELOPMENTS
    • ALNYLAM
      • Takeda Alliance
      • Other Discovery and Development Alliances
        • Isis Collaboration
      • Novartis Broad Alliance
      • Product Alliances
        • Kyowa Hakko Kirin Alliance
        • Cubist Alliance
      • Government Funding
        • NIH Contract
          • TABLE 56: ALNYLAM: PIPELINE
    • TEKMIRA
      • Funding
      • Tekmira's LNP Technology
        • TKM-ApoB
      • TKM-PLK1
    • PHASE I/II TKM-PLK1 CLINICAL TRIAL
      • TKM-Ebola
      • Roche
      • Merck
      • Bristol-Myers Squibb
        • TABLE 57: TEKMIRA'S PIPELINE 17
    • HUMAN CLINICAL TRIAL OF TKM-EBOLA
    • RXI PHARMACEUTICALS
      • Pipeline
        • TABLE 58: RXi PHARMACEUTICALS' DEVELOPMENT PIPELINE
      • RXi 109
    • CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND SCARRING
      • Clinical Program
      • Phase 2
      • RXi Agreements
        • Philips
        • Other Collaborative Agreements
      • Scientific Achievements
      • NIH Grant
    • MARINA BIOTECH
      • Pipeline
        • TABLE 59: MARINA BIOTECH'S DEVELOPMENT PIPELINE
      • Revenue
      • Ongoing Collaborations
        • Beth Israel Deaconess Medical Center-Boston, Mass.
        • Institut Pasteur
        • University of British Columbia (UBC)/Vancouver Prostate Centre (VPC)
        • University of Helsinki
          • TABLE 60: MARINA BIOTECH SELECTED COLLABORATIONS
    • CALANDO PHARMACEUTICALS
      • CALAA-01
    • ISIS PHARMACEUTICALS
      • Pipeline
        • TABLE 61: ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE
      • Strategic Alliances
      • Pharmaceutical Partners
    • SILENCE THERAPEUTICS
      • Proprietary Delivery Technologies
      • Pipeline
        • TABLE 62: SILENCE THERAPEUTICS, DEVELOPMENT PIPELINE
      • Collaborations
        • Quark Pharmaceuticals
      • Clinical Studies
        • TABLE 63: QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS
      • Pipeline
        • TABLE 64: QUARK PHARMACEUTICALS-DEVELOPMENT PIPELINE, 2010
      • QPI-1002
    • ROCHE
    • MERCK
    • SIRNAOMICS
      • TABLE 65: SIRNA THERAPEUTIC PROGRAM
    • STP702 (FluQuit): siRNA Therapeutics against Influenza Infection (Pandemic Flu)
    • STP601 (Acurita) siRNA Therapeutics for AMD and Retinopathy
    • STP705 (Cutasil) siRNA Therapeutics for Skin Scarless Wound Healing (SSWH)
    • STP503 (Trisilensa) siRNA Therapeutics for Breast Cancer
  • ACCESS PHARMACEUTICALS
  • KEY MIRNA THERAPEUTIC COMPANIES
    • MIRNA THERAPEUTICS
      • Pipeline
        • TABLE 66: MIRNA, DEVELOPMENT PIPELINE
  • MRX34
    • REGULUS
      • Pipeline
        • TABLE 67: MIRNA PROGRAMS
  • LOCAL THERAPY
  • DRUG DELIVERY IN CANCER
  • RNAI MARKETPLACE CHALLENGES
  • RNAI'S GROWTH AND FUTURE
    • CONCLUSIONS

CHAPTER 9 - COMPANY PROFILES

  • RNAI-DISCOVERY AND GROWTH
  • COMPANY PROFILES
    • ACCESS PHARMACEUTICALS
    • ALNYLAM PHARMACEUTICALS
    • AMBION
    • APARNABIO
    • ARMAGEN TECHNOLOGIES
    • ARROWHEAD RESEARCH
    • ASURAGEN
    • B-BRIDGE INTERNATIONAL
    • BIO-RAD LABORATORIES
    • CALANDO PHARMACEUTICALS
    • CLONTECH LABORATORIES
    • CYNTELLECT
    • DHARMACON
    • DICERNA PHARMACEUTICALS
    • GENECOPOEIA
    • GENETHERA
    • GENLANTIS
    • GENOSENSOR
    • GENERAL RESEARCH LABORATORY
    • IMGENEX
    • INTEGRATED DNA TECHNOLOGIES (IDT)
    • INVITROGEN
    • INVIVOGEN
    • ISIS PHARMACEUTICALS
    • MARINA BIOTECH
    • MERCK
    • MIRAGEN THERAPEUTICS
    • MIRNA THERAPEUTICS INC.
    • NEW ENGLAND BIOLABS
    • OPEN BIOSYSTEMS
    • ORIGENE TECHNOLOGIES
    • PANOMICS
    • PHASERX
    • PROMEGA CORP.
    • PRONAI THERAPEUTICS
    • QUARK PHARMACEUTICALS
    • REGULUS THERAPEUTICS
    • RXI PHARMACEUTICALS
    • SIGMA-ALDRICH
    • SILENCE THERAPEUTICS
    • SIRNAOMICS
    • SOLSTICE BIOLOGICS
    • SOMAGENICS
    • SYSTEM BIOSCIENCES
    • TACERE THERAPEUTICS
    • TEKMIRA PHARMACEUTICALS CORP.
  • COMPANY PROFILES-EUROPE
    • ACTIGENICS
    • AMAXA
    • CENIX BIOSCIENCE
    • EXIQON
    • GENOVIS
    • PROSENSA HOLDING
    • QIAGEN
    • RNAX
    • SANTARIS PHARMA
  • COMPANY PROFILES-ASIA-PACIFIC
    • ALPHAGEN
    • BENITEC
    • BIONEER
      • U.S.
    • CYTOPATHFINDER INC. INC.
    • GENESIS RESEARCH & DEVELOPMENT CORP.
    • KOKEN CO. LTD.
    • ONCOLYS BIOPHARMA INC. INC.
    • SHANGHAI GENEPHARMA CO. LTD.
    • SHANGHAI GENOMICS
    • TRANSGENE BIOTEK

CHAPTER 10 - MARKET SHIFTS IN RNAI SPACE

  • INTELLECTUAL PROPERTY AND PATENT ASPECTS
    • TABLE 68: MAJOR RNAI COMPANIES IN THE U.S.- PATENT DISTRIBUTION
    • FUTURE DEVELOPMENTS
    • SOME SELECTED PATENTS
    • RNAI PLATFORMS
    • SIRNA LITIGATIONS
  • RECENT PATENT NEWS
    • TABLE 69: PATENTS
  • LICENSES FOR RNAI PATENTS
  • KEY COMPANIES AND PATENTS
    • ALNYLAM
    • RXI
    • ISIS
    • QUARK
    • BENITEC
  • PARTNERSHIPS, ALLIANCES, MERGERS AND ACQUISITIONS
    • ALNYLAM COLLABORATORS: SIGNIFICANT NEW ADVANCES IN RNAI DELIVERY
    • ALNYLAM, MEDTRONIC, AND CHDI FOUNDATION
    • ALNYLAM AND TEKMIRA
  • CONCLUSIONS

CHAPTER 11 - BIBLIOGRAPHY

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION
    • TABLE 2: THERAPEUTICALLY TARGETED APTAMERS
    • TABLE 3: REQUIRED STEPS FOR DEVELOPING EFFECTIVE RNAI DRUG
    • TABLE 4: ROLE OF DRUG DELIVERY
    • TABLE 5: DIFFERENT RNAI DELIVERY APPROACHES
    • TABLE 6: COMPANIES WITH PLASMID RNAI VECTORS
    • TABLE 7: RNAI VIRAL VECTOR DELIVERY METHODS
    • TABLE 8: LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES
    • TABLE 9: THERAPEUTIC STRATEGIES
    • TABLE 10: SIMPLE EXCIEPIENTS FOR RNAI DELIVERY
    • TABLE 11: CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS
    • TABLE 12: POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY
    • TABLE 13: LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY
    • TABLE 14: COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA
    • TABLE 15: THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE
    • TABLE 16: RECENT UPDATES: RNAI CLINICAL TRIALS
    • TABLE 17: CLINICAL TRIALS: RNAI-SYSTEMIC DELIVERY
    • TABLE 18: GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 19: GLOBAL TOOLS, REAGENTS AND THERAPEUTIC MARKET FOR RNAI, THROUGH 2018 ($ MILLIONS)
    • TABLE 20: RNAI COMPANIES WITH TRANSFECTION REAGENTS
    • TABLE 21: IN VIVO DELIVERY
    • TABLE 22: VIRAL BASED DELIVERY TECHNOLOGIES
    • TABLE 23: RNAI TOOL/REAGENT COMPANIES
    • TABLE 24: GLOBAL PHARMACEUTICAL SALES AND FORECAST THROUGH 2018 ($ BILLIONS)
    • TABLE 25: TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 ($ BILLIONS)
    • TABLE 26: TOP 25 PHARMACEUTICAL COMPANIES, GLOBAL SALES, 2012 AND 2013 ($ MILLIONS)
    • TABLE 27: TWELVE LARGEST PHARMACEUTICAL COMPANIES 2010 ($ MILLIONS)
    • TABLE 28: TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 29: KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET
    • TABLE 30: GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 31: GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 32: GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST THROUGH 2018 ($ MILLIONS)
    • TABLE 35: TOP ASTHMA AND COPD DRUGS
    • TABLE 36: GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 38: GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 40: GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: NON-VIRAL SIRNAS
    • TABLE 42: KEY RNAI COMPANIES
    • TABLE 43: LIPID-BASED TECHNOLOGIES-COMPANIES
    • TABLE 44: POLYMER-BASED AND LIPOSOMAL RNAI DELIVERY SYSTEMS (%)
    • TABLE 45: NANOPARTICLES TECHNOLOGIES-COMPANIES
    • TABLE 46: SINGLE RNAI DELIVERY TECHNOLOGIES, COMPANIES
    • TABLE 47: SELECTED RNAI-BASED DRUGS IN DEVELOPMENT
    • TABLE 48: COMMERCIAL POTENTIAL OF RNAI
    • TABLE 49: GLOBAL MARKET FOR THERAPEUTIC RNAI, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: RNAI THERAPEUTIC COMPANIES
    • TABLE 51: ONGOING RNAI CLINICAL TRIALS: NANOPARTICLE DRUG DELIVERY
    • TABLE 52: TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: TOTAL MIRNA MARKET SALES, 2008 (%)
    • TABLE 54: MAJOR RNAI LICENSING DEALS, 2005-2010
    • TABLE 55: SYSTEMIC DELIVERY TECHNOLOGIES, COMPANIES
    • TABLE 56: ALNYLAM: PIPELINE
    • TABLE 57: TEKMIRA'S PIPELINE 17
    • TABLE 58: RXI PHARMACEUTICALS' DEVELOPMENT PIPELINE
    • TABLE 59: MARINA BIOTECH'S DEVELOPMENT PIPELINE
    • TABLE 60: MARINA BIOTECH SELECTED COLLABORATIONS
    • TABLE 61: ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE
    • TABLE 62: SILENCE THERAPEUTICS, DEVELOPMENT PIPELINE
    • TABLE 63: QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS
    • TABLE 64: QUARK PHARMACEUTICALS-DEVELOPMENT PIPELINE, 2010
    • TABLE 65: SIRNA THERAPEUTIC PROGRAM
    • TABLE 66: MIRNA, DEVELOPMENT PIPELINE
    • TABLE 67: MIRNA PROGRAMS
    • TABLE 68: MAJOR RNAI COMPANIES IN THE U.S.- PATENT DISTRIBUTION
    • TABLE 69: PATENTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2013-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL RNAI RESEARCH SALES, 2010-2018 ($ MILLIONS)
    • FIGURE 2: GLOBAL TOTAL MARKET FOR RNAI, 2012-2018 ($ MILLIONS)
    • FIGURE 3: GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($ BILLIONS)
    • FIGURE 4: TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 5: GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 6: GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($ MILLIONS)
    • FIGURE 7: GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 8: GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 9: U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 10: GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 11: GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($ MILLIONS)
    • FIGURE 12: GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS)
    • FIGURE 13: GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 ($ MILLIONS)
    • FIGURE 14: GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES, MARKET, 2012-2018 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR THERAPEUTIC RNAI, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 16: TOTAL MIRNA MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
Back to Top